Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA ; volume:21 ; number:1 ; day:3 ; month:10 ; year:2023 ; pages:1-22 ; date:12.2023
Journal of nanobiotechnology ; 21, Heft 1 (3.10.2023), 1-22, 12.2023
- Urheber
-
Zhang, Shushan
Huang, Yongquan
Pi, Songying
Chen, Hui
Ye, Feile
Wu, Chaoqun
Li, Liujun
Ye, Qing
Lin, Yuhong
Su, Zhongzhen
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12951-023-02067-y
- URN
-
urn:nbn:de:101:1-2024020907542287829749
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhang, Shushan
- Huang, Yongquan
- Pi, Songying
- Chen, Hui
- Ye, Feile
- Wu, Chaoqun
- Li, Liujun
- Ye, Qing
- Lin, Yuhong
- Su, Zhongzhen
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1